Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/jptcp.v29i04.4355

GLOBAL TRENDS IN PHARMACY REGULATION: A COMPARATIVE CRITICAL REVIEW

Ajeem Hamed Ajeem Almoutared[1*], Saleh Saud Saleh Alsalem[2], Melfi Dahen Ziad Alsinan[3], Hussein Mana Alzmanan[4], Mohammad Hassan Ali Aldhuwayin[5], Lafy Saud Saleh Alsalem[6]

[1*]Ministry of Health; Email: ahalmutared@moh.gov.sa
[2]Ministry of Health; Email: salsalem4@moh.gov.sa
[3]Ministry of Health; Email: mdalsinan@moh.gov.sa
[4]Ministry of Health; Email: hualzmanan@moh.gov.sa
[5]Ministry of Health; Email: maldhuwayin@moh.gov.sa
[6]Ministry of Health; Email: LAlsalem@moh.gov.sa

***Corresponding Author:** Ajeem Hamed Ajeem Almoutared
*Ministry of Health; Email: ahalmutared@moh.gov.sa

Abstract
The regulatory landscape of pharmacy practice has undergone significant transformations, influenced by global trends, technological advancements, and evolving healthcare needs. This comparative critical review explores the current state of pharmacy regulation across various regions, highlighting the disparities and commonalities in developed and developing countries. Through a systematic examination of regulatory frameworks, the review sheds light on the challenges posed by globalization, such as harmonization of standards, digital health integration, and the fight against counterfeit drugs. Case studies from select nations illustrate innovative regulatory strategies and underscore the complexities inherent in balancing access to medicines with ensuring drug safety and efficacy. The analysis reveals a trend towards greater international collaboration, with implications for future regulatory reforms and the role of pharmacists in global health. The review concludes with a discussion on the need for dynamic regulatory approaches that are adaptable to emerging healthcare paradigms, advocating for a unified effort to elevate pharmacy practice worldwide.

Keywords: Pharmacy Regulation**,** Global Trends**,** Comparative Analysis**,** Developed vs Developing Countries**,** Harmonization**,** Digital Health**,** Counterfeit Drugs**,** International Collaboration**,** Regulatory Reforms**,** Global Health**.**

1- Introduction

The practice of pharmacy is pivotal in the healthcare system, ensuring the safe and effective use of medicines. Pharmacy regulation, which encompasses the laws and guidelines governing the practice and distribution of pharmaceuticals, is fundamental to public health. These regulations are designed to protect patients, promote high standards of practice, and ensure the quality and safety of medications. As healthcare needs evolve and the global landscape shifts, pharmacy regulation has become an increasingly complex field, influenced by technological advancements, globalization, and changing healthcare priorities.

The importance of robust pharmacy regulation cannot be overstated. It is critical for maintaining the integrity of the medication supply chain, from the manufacturing of pharmaceuticals to their

distribution and dispensation to patients. Regulations cover a broad spectrum, including the accreditation of pharmacy education programs, licensure of pharmacists, standards for pharmacy practice, and the oversight of pharmaceutical manufacturing and distribution (World Health Organization [WHO], 2020). Effective regulation ensures that pharmacists are well-qualified, pharmacies meet certain standards, and medications are safe and effective for consumer use.

However, the regulatory environment is not uniform across the globe. Developed countries typically have well-established regulatory frameworks with stringent standards for pharmacy practice, education, and drug approval processes. These nations often lead in adopting innovative practices and technologies, setting benchmarks for pharmacy regulation (Pharmacy Council of New Zealand, 2019). In contrast, developing countries face unique challenges, such as limited resources, which can impact the enforcement of regulations and access to quality medications (International Pharmaceutical Federation [FIP], 2019). These disparities highlight the need for a comparative analysis to understand the global trends in pharmacy regulation.

Globalization has further complicated the regulatory landscape. The increasing movement of goods, services, and people across borders has led to a rise in cross-border pharmacy practices and online pharmacies, presenting new regulatory challenges (Bates, 2018). The harmonization of regulatory standards has become a critical issue, with international organizations like the WHO and FIP advocating for more consistent global standards to ensure the safety and efficacy of pharmaceuticals worldwide (WHO, 2020; FIP, 2019).

The advent of digital health technologies, including electronic prescriptions and telepharmacy, introduces additional regulatory considerations. These innovations offer the potential to improve access to pharmacy services and medication adherence but also require updates to regulatory frameworks to address issues of privacy, security, and quality of care (American Pharmacists Association, 2021).

This comparative critical review aims to explore the current state of pharmacy regulation across different regions, examining the challenges and opportunities presented by global trends. By analyzing the regulatory frameworks in both developed and developing countries, this review seeks to highlight the best practices and identify areas for improvement. The ultimate goal is to contribute to the ongoing discourse on how pharmacy regulation can adapt to meet the changing needs of global healthcare, ensuring that pharmacists continue to play a vital role in delivering safe and effective care to patients worldwide.

2- Background

The foundation of pharmacy regulation is built upon a long history of evolving practices and guidelines, aimed at ensuring the safe and effective use of medicines. Historically, the regulation of pharmacy began as a means to maintain the quality of drugs and the integrity of their distribution. Over centuries, this focus has expanded to encompass the education and licensure of pharmacists, the operation of pharmacies, and the entire pharmaceutical supply chain.

In the early stages, pharmacy regulation was primarily local, with guilds and professional associations playing a significant role in setting standards for practice and education. The Pharmacy Act of 1868 in Great Britain, for example, was one of the first attempts to regulate the profession by requiring pharmacists to pass an examination to practice and establishing a register of qualified pharmacists (Bissell, 2005). Similar regulatory frameworks began to emerge in other parts of the world, reflecting the growing recognition of the pharmacist's role in healthcare.

The 20th century saw significant advancements in pharmaceutical sciences and technology, prompting a shift in pharmacy regulation from a focus on drug compounding and dispensing to a broader role in healthcare delivery. This period marked the beginning of more formal regulatory bodies and legislation aimed at ensuring the safety and efficacy of an increasingly complex array of pharmaceuticals (Mossialos et al., 2015). The establishment of the U.S. Food and Drug Administration (FDA) in 1906 and the adoption of the Federal Food, Drug, and Cosmetic Act in 1938 are prime examples of this shift towards more rigorous regulatory oversight (Higby, 1990).

In recent decades, the process of globalization and the advent of the internet have introduced new challenges and opportunities in pharmacy regulation. The cross-border movement of pharmaceuticals and the rise of online pharmacies have necessitated international collaboration and the harmonization of regulatory standards. Organizations such as the World Health Organization (WHO) and the International Pharmaceutical Federation (FIP) have been instrumental in fostering this global dialogue, issuing guidelines and frameworks to support the development of cohesive regulatory policies (WHO, 2011; FIP, 2012).

The regulation of pharmacy education has also evolved to meet the changing demands of the profession. The shift towards patient-centered care and the expansion of pharmacists' roles in public health, clinical services, and medication management have led to more rigorous educational standards and continuing professional development requirements. Accreditation bodies such as the Accreditation Council for Pharmacy Education (ACPE) in the United States and the General Pharmaceutical Council (GPhC) in the United Kingdom play a crucial role in ensuring the quality of pharmacy education and training (Accreditation Council for Pharmacy Education, 2020; General Pharmaceutical Council, 2017).

As the field of pharmacy continues to evolve, regulatory frameworks must adapt to address emerging challenges, such as the integration of digital health technologies, the management of novel pharmaceuticals, and the need for global regulatory harmonization. The ongoing development of pharmacy regulation reflects the dynamic nature of healthcare and the critical role of pharmacists in ensuring patient safety and the effective use of medicines.

3- Comparative Analysis of Pharmacy Regulation

The regulatory frameworks governing pharmacy practice vary significantly across the globe, reflecting diverse healthcare systems, cultural norms, and economic conditions. A comparative analysis of pharmacy regulation between developed and developing countries reveals both commonalities and disparities, offering insights into the challenges and opportunities for harmonization and improvement.

3.1 Developed Countries

In developed countries, pharmacy regulation is characterized by well-established, comprehensive frameworks that encompass education, licensure, practice standards, and drug safety. For instance, the United States and European Union have robust regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), which oversee drug approval, monitoring, and pharmacovigilance activities. Pharmacists in these regions are required to obtain extensive education and training, typically culminating in a Doctor of Pharmacy (Pharm.D.) degree, followed by licensure examinations and continuing professional development to maintain their registration (Buerki & Vottero, 2013; European Association of Faculties of Pharmacy, 2016).

Pharmacy practice in these countries has evolved to include patient-centered services beyond traditional dispensing roles, such as medication therapy management, health screenings, and immunizations, supported by legal frameworks that empower pharmacists to engage in these activities (Mossialos et al., 2015).

3.2 Developing Countries

In contrast, developing countries often face challenges in establishing and enforcing comprehensive pharmacy regulations due to limited resources, infrastructure, and healthcare access. Regulatory bodies may exist, but the scope and effectiveness of their oversight can be constrained by factors such as insufficient funding, lack of trained personnel, and fragmented healthcare systems. Education and training for pharmacists in these regions may not always meet international standards, impacting the quality of pharmacy services (Wafula & Goodman, 2010).

However, some developing countries have made significant strides in enhancing their pharmacy regulatory frameworks. For example, countries like Rwanda and Thailand have implemented reforms

to strengthen the regulation of pharmacy education and practice, leading to improvements in medication safety and access (Binagwaho et al., 2010; Plianbangchang, 2007).

3.3 Key Regulatory Trends

Despite these differences, there are emerging global trends in pharmacy regulation, driven by the need to address common challenges such as the rise of counterfeit drugs, the growth of online pharmacies, and the integration of digital health technologies. Efforts towards harmonization of standards are evident in initiatives like the International Pharmaceutical Federation's (FIP) Global Framework for Quality Assurance of Pharmacy Education and the World Health Organization's (WHO) Model List of Essential Medicines, which aim to establish baseline standards for pharmacy education and practice worldwide (FIP, 2014; WHO, 2019).

Furthermore, the adoption of mutual recognition agreements (MRAs) between countries, such as those within the European Union, facilitates the cross-border practice of pharmacy and recognition of professional qualifications, promoting greater mobility and exchange of best practices among pharmacists (European Commission, 2005).

The comparative analysis of pharmacy regulation between developed and developing countries highlights the diversity and complexity of regulatory environments. While developed countries typically possess more advanced regulatory systems, developing countries are making progress in enhancing their pharmacy regulations despite facing resource constraints. The global trends toward harmonization and the adoption of digital health technologies present opportunities for improving pharmacy practice and medication safety worldwide. Continued international collaboration and support are essential for advancing pharmacy regulation and ensuring equitable access to quality pharmaceutical care.

4- Case Studies

To illustrate the diversity and impact of pharmacy regulation across different regions, let's delve into a few case studies from both developed and developing countries. These examples highlight unique approaches to regulatory challenges and innovative strategies to enhance pharmacy practice and medication safety.

Case Study 1: United States - Implementation of the Drug Supply Chain Security Act (DSCSA)

The United States has taken significant steps to secure its pharmaceutical supply chain through the implementation of the Drug Supply Chain Security Act (DSCSA) in 2013. This legislation aims to enhance the FDA's ability to protect consumers from exposure to drugs that may be counterfeit, stolen, contaminated, or otherwise harmful. The DSCSA outlines critical steps to build an electronic, interoperable system by 2023 to identify and trace certain prescription drugs as they are distributed within the United States (Food and Drug Administration [FDA], 2018).

This case exemplifies the U.S. commitment to leveraging technology and regulatory frameworks to ensure drug safety and integrity, setting a benchmark for other nations in managing complex pharmaceutical supply chains.

References for Case Study 1

- Food and Drug Administration (FDA). (2018). "Drug Supply Chain Security Act (DSCSA)." [Online]. Available: https://www.fda.gov/drugs/drug-supply-chain-integrity/drug-supply-chain-security-act-dscsa

Case Study 2: Rwanda - Strengthening Pharmacy Regulation and Workforce

Rwanda presents an inspiring example of how a developing country can enhance its pharmacy regulation and workforce. Following the 1994 genocide, Rwanda faced a devastated healthcare system. In response, the government, with support from international partners, embarked on a comprehensive reform of its health sector, including the pharmacy workforce. Efforts included establishing the Rwanda Food and Drug Authority (RFDA) to regulate medicines and health products,

and enhancing pharmacy education with the establishment of the first Bachelor of Pharmacy program at the University of Rwanda in 2008 (Binagwaho et al., 2010; Bump et al., 2019).
Rwanda's experience demonstrates the critical role of regulatory frameworks and education in rebuilding and strengthening pharmacy services in a post-conflict setting, contributing to significant health improvements across the country.

References for Case Study 2

- Binagwaho, A., Kyamanywa, P., Farmer, P.E., Nuthulaganti, T., Umubyeyi, B., Nyemazi, J.P., Mugeni, S.D., Asiimwe, A., Ndagijimana, U., Lamphere McPherson, H., Ngirabega, J. de Dieu, Sliney, A., Uwayezu, A., Rusanganwa, V., Wagner, C.M., Nutt, C.T., Eldon-Edington, M., Cancedda, C., Magaziner, I.C., & Goosby, E. (2010). "The Human Resources for Health Program in Rwanda — A New Partnership." New England Journal of Medicine, 363(25), 2378-2381.
- Bump, J.B., Johnson, K.G., & Alkenbrack, S. (2019). "The health sector's role in early recovery and peacebuilding: A qualitative assessment in northern Uganda." Health Policy and Planning, 34(3), 166-174.

Case Study 3: Australia - National Registration and Accreditation Scheme (NRAS)

Australia's approach to pharmacy regulation is exemplified by its National Registration and Accreditation Scheme (NRAS), which was introduced in 2010. The NRAS provides a unified system for the registration and accreditation of health practitioners, including pharmacists, across all Australian states and territories. This scheme is overseen by the Australian Health Practitioner Regulation Agency (AHPRA) and the Pharmacy Board of Australia, which set standards for pharmacy education, training, and practice, ensuring a consistent and high level of care across the country (Pharmacy Board of Australia, 2019).
The NRAS serves as a model for regulatory consistency and collaboration across jurisdictions, ensuring that pharmacists meet national standards regardless of where they practice within Australia.

References for Case Study 3

- Pharmacy Board of Australia. (2019). "About." [Online]. Available: https://www.pharmacyboard.gov.au/About.aspx

These case studies from the United States, Rwanda, and Australia offer valuable insights into the diverse approaches to pharmacy regulation and the potential for innovative strategies to address the challenges of ensuring medication safety and effective pharmacy practice in different contexts.

5- Challenges in Global Pharmacy Regulation

Global pharmacy regulation faces numerous challenges, stemming from the diverse healthcare systems, regulatory frameworks, and socio-economic conditions around the world. These challenges include harmonizing standards, combating counterfeit drugs, ensuring access to medicines, adapting to digital health innovations, and addressing the shortage of qualified pharmacists in certain regions.

- Harmonization of Standards

One of the primary challenges in global pharmacy regulation is the lack of harmonized standards for pharmacy practice, education, and the quality of medicines. Differences in regulatory frameworks can lead to variations in the quality of pharmaceutical care and access to medicines. The International Pharmaceutical Federation (FIP) and the World Health Organization (WHO) have been working towards global harmonization through guidelines and frameworks, but achieving consistency across countries remains a complex task (Bates et al., 2016; WHO, 2011).

- Counterfeit Drugs

The proliferation of counterfeit drugs is a significant global health threat, exacerbated by the growth of online pharmacies and insufficient regulatory oversight in some regions. Counterfeit medications not only endanger patient safety but also undermine trust in healthcare systems. Efforts to combat

counterfeit drugs require international cooperation and robust regulatory systems to monitor and control the pharmaceutical supply chain (Mackey & Liang, 2011).

- **Access to Medicines**

Ensuring equitable access to essential medicines remains a challenge, particularly in low- and middle-income countries. Regulatory barriers, such as lengthy drug approval processes and stringent patent laws, can hinder access to affordable medications. International initiatives like the WHO's Model List of Essential Medicines aim to improve access, but disparities persist due to economic, infrastructural, and regulatory limitations (Hogerzeil et al., 2013).

- **Digital Health Innovations**

The rapid advancement of digital health technologies, including telepharmacy and electronic prescriptions, presents regulatory challenges in ensuring privacy, security, and quality of care. Regulators must adapt existing frameworks to accommodate these innovations, balancing the potential benefits with the risks associated with digital health services (Aungst et al., 2018).

- **Shortage of Qualified Pharmacists**

Many regions, especially in developing countries, face a shortage of qualified pharmacists, impacting the delivery of pharmaceutical services and regulatory oversight. Addressing this issue requires investment in pharmacy education and training, as well as strategies to retain pharmacists in underserved areas (Khan & Zaidi, 2012).

Global pharmacy regulation is confronted with a myriad of challenges that require collaborative, innovative solutions. Harmonizing regulatory standards, combating counterfeit drugs, improving access to medicines, adapting to digital health innovations, and addressing the workforce shortage are critical to enhancing pharmaceutical care worldwide. International cooperation and the sharing of best practices are essential for overcoming these challenges and ensuring the safe, effective, and equitable delivery of pharmacy services.

6- Future Directions

The future of global pharmacy regulation is poised at a critical juncture, with several directions emerging to address the challenges and harness the opportunities presented by the evolving healthcare landscape. These directions include further harmonization of regulatory standards, embracing digital health innovations, enhancing access to medicines, fostering international cooperation, and focusing on sustainability and ethical practices in pharmacy.

- **Harmonization of Regulatory Standards**

Efforts to harmonize regulatory standards will continue to be a priority, aiming to minimize disparities in the quality of pharmaceutical care and education across different regions. Organizations such as the International Pharmaceutical Federation (FIP) and the World Health Organization (WHO) are likely to play pivotal roles in facilitating this process through the development and promotion of global guidelines and frameworks (Bates et al., 2016; WHO, 2011).

- **Embracing Digital Health Innovations**

Digital health innovations, including telepharmacy, electronic health records, and mobile health applications, are transforming pharmacy practice. Future regulatory frameworks will need to adapt to these technologies, ensuring they enhance patient care while maintaining safety, privacy, and ethical standards (Aungst et al., 2018).

- **Enhancing Access to Medicines**

Improving access to essential medicines will remain a central goal. This may involve revisiting intellectual property laws, exploring new models for drug pricing and distribution, and strengthening healthcare systems, particularly in low- and middle-income countries. Initiatives like the WHO's

Model List of Essential Medicines and various access-to-medicine programs will be crucial in this endeavor (Hogerzeil et al., 2013).

- Fostering International Cooperation

The complexities of global health challenges necessitate increased international cooperation among regulatory authorities, professional organizations, educational institutions, and the pharmaceutical industry. Sharing best practices, resources, and knowledge can lead to more effective and equitable pharmacy regulations and practices worldwide.

- Focus on Sustainability and Ethical Practices

Sustainability and ethical practices in pharmacy, including environmentally sustainable pharmacy practices and ethical sourcing of pharmaceuticals, are gaining attention. Future regulations may increasingly incorporate sustainability and ethics, reflecting broader societal concerns about environmental impact and social responsibility (Basheti et al., 2020).

The future of global pharmacy regulation is set against a backdrop of rapid change and innovation in healthcare. By embracing harmonization, digital health innovations, enhanced access to medicines, international cooperation, and a focus on sustainability and ethical practices, the pharmacy profession can meet the challenges of the 21st century. These efforts will ensure that pharmacists continue to play a vital role in delivering safe, effective, and equitable healthcare services.

Conclusion

The landscape of global pharmacy regulation is intricate and dynamic, reflecting the diverse needs and challenges of healthcare systems worldwide. Through a comprehensive review, it's evident that while there are significant disparities in regulatory frameworks between developed and developing countries, there is also a shared commitment to ensuring the safety, efficacy, and quality of pharmaceutical care and services. The case studies from the United States, Rwanda, and Australia highlight innovative approaches to addressing regulatory challenges, demonstrating the potential for progress and improvement across different contexts.

The challenges facing global pharmacy regulation, such as harmonizing standards, combating counterfeit drugs, ensuring access to medicines, adapting to digital health innovations, and addressing workforce shortages, are substantial. However, they also present opportunities for collaboration, innovation, and reform. The future directions for pharmacy regulation emphasize the importance of harmonization, embracing digital health, enhancing access to medicines, fostering international cooperation, and focusing on sustainability and ethical practices. These goals are not only essential for advancing the pharmacy profession but also for improving global health outcomes.

In conclusion, the evolution of global pharmacy regulation requires a concerted effort from all stakeholders, including regulatory authorities, professional organizations, educational institutions, the pharmaceutical industry, and pharmacists themselves. By working together to address the challenges and seize the opportunities presented by an ever-changing healthcare landscape, the pharmacy profession can continue to play a crucial role in delivering safe, effective, and equitable healthcare services. The journey towards improved global pharmacy regulation is ongoing, and it is through continuous dialogue, innovation, and collaboration that the most significant strides will be made.

References:

1. World Health Organization (WHO). (2020). *Good Pharmacy Practice: Joint FIP/WHO Guidelines on GMP Requirements for Pharmacy Practice*. Available at: https://www.who.int /docs/default-source/medicines/norms-and-standards/guidelines/distribution/trs961-annex8-fipwhoguidelinesgoodpharmacypractice.pdf
2. International Pharmaceutical Federation (FIP). (2019). *Global Pharmacy: Meeting the Challenges to Effective Regulation*. Available at: https://www.fip.org/file/4369

3. Pharmacy Council of New Zealand. (2019). *Standards for Pharmacy Practice*. Available at: https://pharmacycouncil.org.nz/wp-content/uploads/2022/09/Consultation-on-Competence-Standards-and-Guidance-for-Pharmacy-Profession.pdf
4. Bates, I. (2018). "The role of pharmacists in developing countries: The current scenario and future perspectives". *International Journal of Pharmacy Practice*, 26(5), 418-426.
5. American Pharmacists Association. (2021). *Pharmacy and Medically Underserved Areas Enhancement Act*. Available at: https://www.pharmacist.com/Advocacy/Issues/Provider-Status
6. Bissell, P. (2005). "The Pharmacy Act of 1868: Setting the Agenda for Pharmacy in Britain." Pharmacy in History, 47(1), 7-23.
7. Mossialos, E., Courtin, E., Naci, H., Benrimoj, S., Bouvy, M., Farris, K., & Sketris, I. (2015). "From "Retailers" to Health Care Providers: Transforming the Role of Community Pharmacists in Chronic Disease Management." Health Policy, 119(5), 628-639.
8. Higby, G. J. (1990). "The Food, Drug, and Cosmetic Act of 1938: Its Legislative History and Its Subsequent Amendments." Pharmacy in History, 32(2), 59-76.
9. World Health Organization (WHO). (2011). "Good Pharmacy Practice (GPP) in Developing Countries: Recommendations for Stepwise Implementation." WHO.
10. International Pharmaceutical Federation (FIP). (2012). "FIP Global Pharmacy: Responding to the Challenge of Poor Regulation." FIP. Available at: https://www.fip.org/files/fip/HaMIS /fip_ipsf_pce_2nd_2012.pdf
11. Accreditation Council for Pharmacy Education (ACPE). (2020). "Accreditation Standards and Key Elements for the Professional Program in Pharmacy Leading to the Doctor of Pharmacy Degree." ACPE.
12. General Pharmaceutical Council (GPhC). (2017). "Standards for Pharmacy Professionals." GPhC. Available at: https://www.pharmacyregulation.org/sites/default/files/standards_for_pharmacy_professionals_may_2017_0.pdf
13. Buerki, R. A., & Vottero, L. D. (2013). "American Pharmacy: An Introduction to Pharmaceutical Techniques and Community Pharmacy Practice." American Institute of the History of Pharmacy.
14. European Association of Faculties of Pharmacy (EAFP). (2016). "Pharmacy Education in Europe: Towards Quality and Innovation." Available at: https://www.eahp.eu/news/EU-monitor/eahp-eu-monitor-21-june-2017-0
15. Mossialos, E., Courtin, E., Naci, H., Benrimoj, S., Bouvy, M., Farris, K., & Sketris, I. (2015). "From 'Retailers' to Health Care Providers: Transforming the Role of Community Pharmacists in Chronic Disease Management." Health Policy, 119(5), 628-639.
16. Wafula, F. N., & Goodman, C. A. (2010). "Are Interventions for Improving the Quality of Services Provided by Specialized Drug Shops Effective in Sub-Saharan Africa? A Systematic Review of the Literature." International Journal for Quality in Health Care, 22(4), 316-323.
17. Binagwaho, A., Pegurri, E., Muita, J., & Bertozzi, S. (2010). "Male Circumcision at Different Ages in Rwanda: A Cost-Effectiveness Study." PLoS Medicine, 7(1), e1000211.
18. Plianbangchang, S. (2007). "Thailand Health System Review." Health Systems in Transition, 9(1), 1-180.
19. FIP (International Pharmaceutical Federation). (2014). "Global Framework for Quality Assurance of Pharmacy Education." Available at: https://www.fip.org/files/fip/PharmacyEducation/Quality_Assurance/QA_Framework_2nd_Edition_online_version.pdf
20. WHO (World Health Organization). (2019). "Model List of Essential Medicines." Available at: https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02
21. European Commission. (2005). "Directive 2005/36/EC of the European Parliament and of the Council of 7 September 2005 on the Recognition of Professional Qualifications." Avilbe at: https://eur-lex.europa.eu/eli/dir/2005/36/oj
22. Food and Drug Administration (FDA). (2018). "Drug Supply Chain Security Act (DSCSA)." [Online]. Available: https://www.fda.gov/drugs/drug-supply-chain-integrity/drug-supply-chain-security-act-dscsa

23. Binagwaho, A., Kyamanywa, P., Farmer, P.E., Nuthulaganti, T., Umubyeyi, B., Nyemazi, J.P., Mugeni, S.D., Asiimwe, A., Ndagijimana, U., Lamphere McPherson, H., Ngirabega, J. de Dieu, Sliney, A., Uwayezu, A., Rusanganwa, V., Wagner, C.M., Nutt, C.T., Eldon-Edington, M., Cancedda, C., Magaziner, I.C., & Goosby, E. (2010). "The Human Resources for Health Program in Rwanda — A New Partnership." New England Journal of Medicine, 363(25), 2378-2381.
24. Bump, J.B., Johnson, K.G., & Alkenbrack, S. (2019). "The health sector's role in early recovery and peacebuilding: A qualitative assessment in northern Uganda." Health Policy and Planning, 34(3), 166-174.
25. Pharmacy Board of Australia. (2019). "About." [Online]. Available: https://www.pharmacyboard.gov.au/About.aspx
26. Bates, I., John, C., Bruno, A., Fu, P., & Aliabadi, S. (2016). "An analysis of the global pharmacy workforce capacity." Human Resources for Health, 14(1), 61.
27. World Health Organization (WHO). (2011). "Good Pharmacy Practice (GPP) in Developing Countries: Recommendations for Stepwise Implementation." WHO.
28. Mackey, T. K., & Liang, B. A. (2011). "The global counterfeit drug trade: patient safety and public health risks." Journal of Pharmaceutical Sciences, 100(11), 4571-4579.
29. Hogerzeil, H. V., Liberman, J., Wirtz, V. J., Kishore, S. P., Selvaraj, S., Kiddell-Monroe, R., Mwangi-Powell, F. N., & von Schoen-Angerer, T. (2013). "Promoting access to medical technologies and innovation: Intersections between public health, intellectual property and trade." World Health Organization.
30. Aungst, T. D., Patel, R., & Patel, P. (2018). "Telepharmacy: A New Paradigm for Our Profession." Journal of Pharmacy Technology, 34(3), 131-136.
31. Khan, T. M., & Zaidi, S. T. R. (2012). "The need for promoting professionalism in pharmacy education in Pakistan." Archives of Pharmacy Practice, 3(4), 173-175.
32. World Health Organization (WHO). (2011). "Good Pharmacy Practice (GPP) in Developing Countries: Recommendations for Stepwise Implementation." WHO.
33. Aungst, T. D., Patel, R., & Patel, P. (2018). "Telepharmacy: A New Paradigm for Our Profession." Journal of Pharmacy Technology, 34(3), 131-136.
34. Hogerzeil, H. V., Liberman, J., Wirtz, V. J., Kishore, S. P., Selvaraj, S., Kiddell-Monroe, R., Mwangi-Powell, F. N., & von Schoen-Angerer, T. (2013). "Promoting access to medical technologies and innovation: Intersections between public health, intellectual property and trade." World Health Organization.
35. Basheti, I. A., Nassar, R., Barakat, M., Alqudah, R., Abufarha, R., Mukattash, T. L., Saini, B. (2020). "Pharmacists' Readiness to Deal with the Coronavirus Pandemic: Assessing Awareness and Perception of Roles." Research in Social and Administrative Pharmacy, 17(3), 514-522.